| . | Mean ± SD or proportion . | Median (IQR) . |
|---|---|---|
| Age (years) | 58 ± 9 | 60 (53–64) |
| Males (%) | 70.8 | – |
| Persistent AF (%) | 35.9 | – |
| Weight (kg) | 91 ± 16 | 90 (80–100) |
| Height (cm) | 177 ± 10 | 178 (170–184) |
| BMI (kg/m2) | 29.0 ± 4.2 | 28.7 (25.9–31.6) |
| BSA (m2) | 2.07 ± 0.21 | 2.07 (1.93–2.23) |
| CHA2DS2VASc score | 1.5 ± 1.3 | 1 (1–2) |
| LV dysfunction (EF < 0.55) (%) | 26.5 | – |
| LA diameter (mm) | 43 ± 5 | 43 (43–46) |
| Procedure time (min) | 259 ± 69 | 252 (205–307) |
| Fluoroscopic time (min) | 21 ± 12 | 19 (12–27) |
| Radiofrequency time (s) | 2699 ± 1359 | 2512 (1755–3459) |
| Complex procedure (%) | 43.5 | – |
| Repeat ablation (%) | 25.4 | – |
| Robotic procedure (%) | 22.4 | – |
| Hypertension (%) | 54.9 | – |
| Heart failure (%) | 1.9 | – |
| Diabetes (%) | 9.8 | – |
| Previous stroke/TIA (%) | 6.3 | – |
| CAD (%) | 10.3 | – |
| PVD (%) | 1.1 | – |
| Warfarin (%) | 69.4 | – |
| Antiplatelet drugs (%) | 22.5 | – |
| Amiodarone (%) | 24.0 | – |
| Beta blockers (%) | 68.3 | – |
| ACEI/ARB (%) | 35.2 | – |
| . | Mean ± SD or proportion . | Median (IQR) . |
|---|---|---|
| Age (years) | 58 ± 9 | 60 (53–64) |
| Males (%) | 70.8 | – |
| Persistent AF (%) | 35.9 | – |
| Weight (kg) | 91 ± 16 | 90 (80–100) |
| Height (cm) | 177 ± 10 | 178 (170–184) |
| BMI (kg/m2) | 29.0 ± 4.2 | 28.7 (25.9–31.6) |
| BSA (m2) | 2.07 ± 0.21 | 2.07 (1.93–2.23) |
| CHA2DS2VASc score | 1.5 ± 1.3 | 1 (1–2) |
| LV dysfunction (EF < 0.55) (%) | 26.5 | – |
| LA diameter (mm) | 43 ± 5 | 43 (43–46) |
| Procedure time (min) | 259 ± 69 | 252 (205–307) |
| Fluoroscopic time (min) | 21 ± 12 | 19 (12–27) |
| Radiofrequency time (s) | 2699 ± 1359 | 2512 (1755–3459) |
| Complex procedure (%) | 43.5 | – |
| Repeat ablation (%) | 25.4 | – |
| Robotic procedure (%) | 22.4 | – |
| Hypertension (%) | 54.9 | – |
| Heart failure (%) | 1.9 | – |
| Diabetes (%) | 9.8 | – |
| Previous stroke/TIA (%) | 6.3 | – |
| CAD (%) | 10.3 | – |
| PVD (%) | 1.1 | – |
| Warfarin (%) | 69.4 | – |
| Antiplatelet drugs (%) | 22.5 | – |
| Amiodarone (%) | 24.0 | – |
| Beta blockers (%) | 68.3 | – |
| ACEI/ARB (%) | 35.2 | – |
BMI, body mass index; BSA, body surface area; LV, left ventricle; EF, ejection fraction; CAD, coronary artery disease; PAD, peripheral artery disease; ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker.
| . | Mean ± SD or proportion . | Median (IQR) . |
|---|---|---|
| Age (years) | 58 ± 9 | 60 (53–64) |
| Males (%) | 70.8 | – |
| Persistent AF (%) | 35.9 | – |
| Weight (kg) | 91 ± 16 | 90 (80–100) |
| Height (cm) | 177 ± 10 | 178 (170–184) |
| BMI (kg/m2) | 29.0 ± 4.2 | 28.7 (25.9–31.6) |
| BSA (m2) | 2.07 ± 0.21 | 2.07 (1.93–2.23) |
| CHA2DS2VASc score | 1.5 ± 1.3 | 1 (1–2) |
| LV dysfunction (EF < 0.55) (%) | 26.5 | – |
| LA diameter (mm) | 43 ± 5 | 43 (43–46) |
| Procedure time (min) | 259 ± 69 | 252 (205–307) |
| Fluoroscopic time (min) | 21 ± 12 | 19 (12–27) |
| Radiofrequency time (s) | 2699 ± 1359 | 2512 (1755–3459) |
| Complex procedure (%) | 43.5 | – |
| Repeat ablation (%) | 25.4 | – |
| Robotic procedure (%) | 22.4 | – |
| Hypertension (%) | 54.9 | – |
| Heart failure (%) | 1.9 | – |
| Diabetes (%) | 9.8 | – |
| Previous stroke/TIA (%) | 6.3 | – |
| CAD (%) | 10.3 | – |
| PVD (%) | 1.1 | – |
| Warfarin (%) | 69.4 | – |
| Antiplatelet drugs (%) | 22.5 | – |
| Amiodarone (%) | 24.0 | – |
| Beta blockers (%) | 68.3 | – |
| ACEI/ARB (%) | 35.2 | – |
| . | Mean ± SD or proportion . | Median (IQR) . |
|---|---|---|
| Age (years) | 58 ± 9 | 60 (53–64) |
| Males (%) | 70.8 | – |
| Persistent AF (%) | 35.9 | – |
| Weight (kg) | 91 ± 16 | 90 (80–100) |
| Height (cm) | 177 ± 10 | 178 (170–184) |
| BMI (kg/m2) | 29.0 ± 4.2 | 28.7 (25.9–31.6) |
| BSA (m2) | 2.07 ± 0.21 | 2.07 (1.93–2.23) |
| CHA2DS2VASc score | 1.5 ± 1.3 | 1 (1–2) |
| LV dysfunction (EF < 0.55) (%) | 26.5 | – |
| LA diameter (mm) | 43 ± 5 | 43 (43–46) |
| Procedure time (min) | 259 ± 69 | 252 (205–307) |
| Fluoroscopic time (min) | 21 ± 12 | 19 (12–27) |
| Radiofrequency time (s) | 2699 ± 1359 | 2512 (1755–3459) |
| Complex procedure (%) | 43.5 | – |
| Repeat ablation (%) | 25.4 | – |
| Robotic procedure (%) | 22.4 | – |
| Hypertension (%) | 54.9 | – |
| Heart failure (%) | 1.9 | – |
| Diabetes (%) | 9.8 | – |
| Previous stroke/TIA (%) | 6.3 | – |
| CAD (%) | 10.3 | – |
| PVD (%) | 1.1 | – |
| Warfarin (%) | 69.4 | – |
| Antiplatelet drugs (%) | 22.5 | – |
| Amiodarone (%) | 24.0 | – |
| Beta blockers (%) | 68.3 | – |
| ACEI/ARB (%) | 35.2 | – |
BMI, body mass index; BSA, body surface area; LV, left ventricle; EF, ejection fraction; CAD, coronary artery disease; PAD, peripheral artery disease; ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
